New
IAS Foundation Course (Pre. + Mains) - Delhi: 20 Jan, 11:30 AM | Prayagraj: 5 Jan, 10:30 AM | Call: 9555124124

Chimeric Antigen Receptor T-cell Therapy

  • The 4th June, 2021 was a historic day for Tata Memorial Hospital, IIT Bombay team and cancer care in India as the first CAR-T cell therapy (a type of gene therapy) was done. The CAR-T cells were designed and manufactured at Bioscience and Bioengineering (BSBE) department of IIT Bombay.
  • The Chimeric Antigen Receptor T-cell (CAR-T) therapy has emerged as a breakthrough in cancer treatment. Clinical trials conducted globally have shown promising results in end stage patients, especially in patients suffering from Acute Lymphocytic Leukemia.
  • Till now this technology was not available in India. CAR-T cell therapy costs 3-4 crore (INR). The manufacturing complexity is a major reason for the therapy cost. In order to promote and support development of CAR-T cell technology against cancer and other diseases, BIRAC and DBT have taken initiatives.
  • The CAR-T cells were devloped with support from Biotechnology Industry Research Assistance Councilthrough National Biopharma Mission. BIRAC is a not-for-profit Section 8, Schedule B, Public Sector Enterprise, set up by Department of Biotechnology.
« »
  • SUN
  • MON
  • TUE
  • WED
  • THU
  • FRI
  • SAT
Have any Query?

Our support team will be happy to assist you!

OR
X